Bristol-Myers Squibb
Market Cap
US$148.7b
Last Updated
2020/02/19 23:44 UTC
Data Sources
Company Financials +
Executive Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential established dividend payer.
Similar Companies
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMY has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.9%
BMY
-1.0%
US Pharmaceuticals
0.5%
US Market
1 Year Return
28.1%
BMY
6.7%
US Pharmaceuticals
20.3%
US Market
Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: BMY exceeded the US Market which returned 20.3% over the past year.
Shareholder returns
| BMY | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.9% | -1.0% | 0.5% |
| 30 Day | -1.5% | -3.3% | 2.0% |
| 90 Day | 15.6% | 5.7% | 9.4% |
| 1 Year | 32.4%28.1% | 9.4%6.7% | 22.8%20.3% |
| 3 Year | 29.6%18.7% | 25.9%16.9% | 50.1%40.4% |
| 5 Year | 22.9%7.3% | 21.3%9.0% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Bristol-Myers Squibb Company Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?2 weeks ago | Simply Wall St
Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Rather Sparingly1 month ago | Simply Wall St
How Should Investors Feel About Bristol-Myers Squibb Company's (NYSE:BMY) CEO Pay?Valuation
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($65.71) is trading below our estimate of fair value ($189.05)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is poor value based on its PE Ratio (32.6x) compared to the Pharmaceuticals industry average (21.5x).
PE vs Market: BMY is poor value based on its PE Ratio (32.6x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: BMY is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: BMY is overvalued based on its PB Ratio (6.1x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
82.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY's forecast earnings growth (82.4% per year) is above the savings rate (1.7%).
Earnings vs Market: BMY's earnings (82.4% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BMY's revenue (8.1% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BMY's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be high in 3 years time (25.4%)
Next Steps
Past Performance
How has Bristol-Myers Squibb performed over the past 5 years?
16.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY has a high level of non-cash earnings.
Growing Profit Margin: BMY's current net profit margins (13.2%) are lower than last year (21.8%).
Past Earnings Growth Analysis
Earnings Trend: BMY's earnings have grown by 16.7% per year over the past 5 years.
Accelerating Growth: BMY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BMY had negative earnings growth (-30.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.4%).
Return on Equity
High ROE: BMY's Return on Equity (19.5%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($40.2B) exceed its short term liabilities ($10.5B).
Long Term Liabilities: BMY's short term assets ($40.2B) exceed its long term liabilities ($29.2B).
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (141.9%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 52.2% to 141.9% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (33.6%).
Interest Coverage: BMY's interest payments on its debt are well covered by EBIT (37x coverage).
Balance Sheet
Inventory Level: BMY has a low level of unsold assets or inventory.
Debt Coverage by Assets: BMY's debt is covered by short term assets (assets are 1.6x debt).
Next Steps
Dividend
What is Bristol-Myers Squibb's current dividend yield, its reliability and sustainability?
2.74%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: BMY's dividend (2.74%) is higher than the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: BMY's dividend (2.74%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (83.3%), BMY's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (25.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Giovanni Caforio (54yo)
4.8yrs
Tenure
US$19,379,755
Compensation
Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD19.38M) is above average for companies of similar size in the US market ($USD10.78M).
Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.8yrs | US$19.38m | 0.016% $24.5m | |
| Executive VP & General Counsel | 13yrs | US$6.24m | 0.025% $36.5m | |
| Executive VP & Head of Integration | 0.2yrs | US$7.89m | 0.017% $25.9m | |
| Executive VP and President of Global Product Development & Supply | 2.8yrs | US$4.13m | 0.0014% $2.1m | |
| Executive VP & CFO | 0.3yrs | no data | 0.00091% $1.4m | |
| Executive VP & Chief Information Officer | 8.1yrs | no data | 0.0060% $8.9m | |
| Executive Vice President of Investor Relations | 3.1yrs | no data | 0.0033% $4.9m | |
| Senior VP & Chief Compliance and Ethics Officer | 2.1yrs | no data | 0.00074% $1.1m | |
| Executive VP & Chief Human Resources Officer | 3.7yrs | no data | 0.0014% $2.1m | |
| Head of US Drug Makers - India | 5.6yrs | no data | no data |
3.4yrs
Average Tenure
57yo
Average Age
Experienced Management: BMY's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.8yrs | US$19.38m | 0.016% $24.5m | |
| Independent Director | 8.1yrs | US$325.00k | no data | |
| Independent Director | 12.1yrs | US$340.81k | 0.00010% $148.7k | |
| Lead Independent Director | 2.8yrs | US$388.31k | no data | |
| Independent Director | 12.9yrs | US$355.00k | 0.00015% $223.1k | |
| Independent Director | 6.6yrs | US$307.50k | 0.00057% $847.7k | |
| Independent Director | 3yrs | US$345.00k | 0.000010% $14.9k | |
| Independent Director | 3yrs | US$324.16k | 0.00051% $758.5k | |
| Independent Director | 3.8yrs | US$332.75k | no data | |
| Independent Director | 3yrs | US$337.50k | 0.0012% $1.8m |
3.5yrs
Average Tenure
63yo
Average Age
Experienced Board: BMY's board of directors are considered experienced (3.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Top Shareholders
Company Information
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$148.724b
- Shares outstanding: 2.25b
- Website: https://www.bms.com
Number of Employees
Location
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- 10016
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMY | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1968 |
| BMY * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1968 |
| BRM | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BRM | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BMY | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1968 |
| 0R1F | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1968 |
| BRM | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jan 1968 |
| BMYS | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1968 |
| BMY | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH REP 1 COM USD0.10 | AR | ARS | Mar 2009 | |
| BMYB34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EA REPR 1 COM SHS | BR | BRL | Aug 2012 |
Biography
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; Presage Biosciences; and WindMIL Therapeutics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/19 23:44 |
| End of Day Share Price | 2020/02/19 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.